SeaStar Medical Holding Corporation, a commercial-stage healthcare company dedicated to revolutionizing treatments for critically ill patients experiencing organ failure and life-threatening conditions, has officially announced its participation in the upcoming Life Sciences Investor Forum. The event, scheduled for March 11, 2026, will feature a significant presentation by the company's leadership team.
CEO Presentation Details
Eric Schlorff, the Chief Executive Officer of SeaStar Medical, is set to engage in a comprehensive fireside CEO chat during the forum. This interactive session will be moderated by David Bautz, Senior Biotech Analyst at Zacks Small-Cap Research, providing valuable insights into the company's strategic direction and recent advancements. The presentation is scheduled to begin at 12:00 pm Eastern Time and will be hosted virtually through VirtualInvestorConferences.com.
Interactive Investor Opportunities
The Life Sciences Investor Forum will be conducted as a live, interactive online event, offering both individual and institutional investors, along with advisors and analysts, the chance to participate actively. Attendees will have the unique opportunity to submit questions to SeaStar Medical's management team in real time, fostering direct engagement and transparency. Following the conclusion of the conference, a replay of the webcast will be made available for those unable to attend the live session.
In addition to the main presentation, SeaStar Medical has made arrangements for one-on-one meetings with investors on March 11. Interested parties are encouraged to schedule these personalized sessions in advance to discuss the company's progress and future prospects in greater detail.
Recent Company Milestones
SeaStar Medical has achieved several notable milestones in recent months, underscoring its growth and innovation in the healthcare sector:
- Commercial Expansion: The company has seen increased adoption of its first FDA-approved product, QUELIMMUNE, which is specifically designed for pediatric patients suffering from acute kidney injury (AKI) combined with sepsis or septic conditions.
- Clinical Data Publication: Positive safety and patient outcomes data from the SAVE Surveillance Registry, focusing on pediatric patients treated with QUELIMMUNE therapy, have been published in the esteemed peer-reviewed journal Pediatric Nephrology.
- Ongoing Clinical Trials: Patient enrollment continues in the pivotal NEUTRALIZE-AKI clinical trial, which evaluates the safety and efficacy of the Selective Cytopheretic Device (SCD) therapy in adult patients with AKI in intensive care units. Additionally, the company has initiated the NEUTRALIZE-CRS clinical trial to address patients with acute chronic systolic heart failure complicated by cardiorenal syndrome.
About SeaStar Medical
SeaStar Medical is at the forefront of developing transformative treatments for critically ill patients facing organ failure and potential loss of life. The company's flagship product, QUELIMMUNE (SCD-PED), received approval from the U.S. Food and Drug Administration in 2024, marking it as the only FDA-approved therapy for the ultra-rare condition of life-threatening AKI due to sepsis in critically ill pediatric patients.
The SCD therapy has been granted Breakthrough Device Designation by the FDA for four therapeutic indications, facilitating a potentially accelerated approval pathway and favorable reimbursement frameworks upon commercial launch. Currently, SeaStar Medical is conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy—a severe condition affecting over 200,000 adults annually in the United States, with no effective treatment options currently available.
For further information about SeaStar Medical and its groundbreaking work, visit the official website at www.seastarmedical.com or connect with the company on professional networking platforms such as LinkedIn and X.
